It’s reassuring to know that ATRALIN™ (tretinoin) Gel 0.05% is an aqueous gel that offers a low irritation profile¹ to help patients succeed with their treatment.

The charts below highlight results from two multi-center trials and demonstrate that ATRALIN™ Gel is a smart choice for acne vulgaris that offers excellent tolerability.¹

Incidence of new skin-related adverse reactions^1,*

In two 12-week controlled, multi-center, investigator-blinded, randomized studies of 560 subjects with mild to moderate acne vulgaris.

Percentage of patients with skin-related adverse reactions reported
over the 12 weeks of treatment^1,*

In a 12-week controlled, multi-center, investigator-blinded, randomized study of 1,161 subjects with mild to moderate acne vulgaris.

In these studies, 50% of the patients treated with ATRALIN™ Gel reported one or more adverse reactions and 30% reported treatment-related adverse reactions. In the vehicle group, 29% of patients reported at least one adverse reaction and 5% reported treatment-related events.

Skin related adverse events were defined as dry skin, skin burning sensation, erythema, exfoliative dermatitis, skin exfoliation, pruritus, rash, scaly skin, pain of skin, sunburn, and skin desquamation.

Most skin-related adverse reactions first appear during the first two weeks of treatment with ATRALIN™ Gel, and the incidence rate for skin-related reactions peaks around the second and third week of treatment.

In some patients, skin-related adverse reactions persisted throughout the treatment period.

*Individual results may vary.

Reference: 1. Data on file, CORIA Laboratories, Ltd.